Our SMART Molecules are ready to be tested in human patients for clinical diagnosis of Alzheimer’s disease and Parkinson’s disease.
An incremental step towards the mass distribution of our technology involves generating large quantities of the SMART Molecules by employing cloning procedures following GMP regulations.
For more details on our Phase 1 clinical trials, we invite you to view our Investor Section page to find more materials and information on our current capital raise.
Learn More
Changing the course of Parkinson’s and Alzheimer’s disease.
ICBI is developing breakthrough sciences and therapeutic drugs to help treat the combined total of 65 million individuals around the world battling these diseases. Through the SMART Molecule Technology Platform, ICBI hopes to eradicate other brain and body diseases (e.g. neurodegenerative diseases, cancers).
Crossing the Blood-Brain Barrier to transport therapeutic drugs to the Brain.
ICBI is developing biologics that specifically target pathologic proteins in the central nervous system, thereby offering clinical potential for early diagnosis, monitoring and treatment of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases.
Learn MoreRecent Milestones
Since the company’s inception in 2008, ICBI scientists have published and worked extensively to produce a body of work respected by many institutions across the world.
2021
- Blood-brain barrier permeable peptide compositions, Patent # EP 3,309,171
(05/14/2021)
2020
- Approval of US Patent: Blood-Brain Barrier Permeable Peptide Compositions, US 16/136,058.
- Constructed several expression vectors for optimization of α-Syn-SM.
- Blood-brain barrier permeable peptide compositions, Patent # US 10 / 738,109 (08/11/2020).
2019
- Approval of European Patent: Blood-Brain Barrier Permeable Peptide Compositions, EP2754670A1.
- Demonstrated dose dependent therapeutic effect of Parkinson’s potential drug, α-Syn-SM.
- Submitted a divisional patent application to the US Patent Office (USPTO).
- Blood-brain barrier permeable peptide compositions, Patent # EP2754670A1 (04/24/2019).
2018
- Approval of US Patent: Blood-Brain Barrier Permeable Peptide Compositions, US 10, 112,987 B2.
- Approval of US Patent: Blood-Brain Barrier Permeable Peptide Compositions, US 10, 112,988 B2.
- Submitted a divisional patent application to the European Patent Office.
- Cloned and expressed a-Syn-antibody.
- Blood-brain barrier permeable peptide composition, Patent # US10 / 112988B2 (10/30/2018).
2017
- Approval of European Patent: Blood-Brain Barrier Permeable Peptide Compositions, EP 2664625B1.
- Submitted two divisional patent applications
- Studied therapeutic efficacy of Aβ-SM in transgenic mice.
- Blood-brain barrier permeable peptide compositions Patent # EP 2664625B1 (8/23/2017).
2016
- Successfully completed Michael J. Fox Foundation (MJFF) grant project and submitted report
- Conducted therapeutic efficacy study on Parkinson’s drug (α-Syn-SM) in animal model and presented data at MJFF Annual Parkinson’s Therapeutic Conference in New York – October 23, 2016.
- Demonstrated a substantial reduction of pathogenic Parkinson’s protein, α-synuclein, in vivo
- Dr. Serge Muyldermans (Vrije Universiteit Brussel; Brussels, Belgium) joined our scientific advisory team. Dr. Muylderman is the world’s expert in single-domain antibodies.
- Second European patent approved (EP 23506555)
- Received unsolicited inquiries from seven major pharmaceutical companies
- Methods for using antibodies and analogs thereof, Patent # EP2350655 B1 (12/21/2016)
2015
- Awarded grant from the Michael J. Fox Foundation (MJFF)
- Fifth patent application submitted to the US Patent Office
- Launched collaboration with UC Irvine to study the pharmacodynamics of one of our SMART Molecules (SM)
- SM technology presented at the MJFF in November
- Generated SM for phosphorylated-tau to treat Alzheimer’s disease
- Small Animal PET-Imaging Scanner (Genesys 4) from Sofi Bio established
2014
- Submitted fourth utility patent to the US Patent Office
- Unprecedented live imaging of Parkinson’s disease lesions in the brains of Parkinson’s mice
- Demonstrated BBB uptake and studied pharmacology of α-Syn-SM at the Center of Molecular Imaging, Canada
- Demonstrated integrity of the BBB in Transgenic and Non-Transgenic mice
- Developed tracers for imaging α-synuclein in Parkinson’s disease
- Generated two additional SMs for Alzheimer’s disease and one for Parkinson’s disease
2013
- Awarded Grant from the Michael J. Fox Foundation (MJFF)
- Developed α-Synuclein-Smart Molecule (α-Syn-SM) to diagnose and modify Parkinson’s disease
- Demonstrated proof-of-concept in an animal model: BBB permeability and binding to pathological lesions in the brain of Parkinson’s mice
- Submitted third utility patent to the US Patent Office
2012
- Established BBB permeability of ICBI anti-Alzheimer’s molecule
- Established BBB permeability of anti- Parkinson’s molecule
- Demonstrated proof-of-concept in an animal model: BBB permeability and binding to pathological lesions in the brain of Alzheimer’s mice
A-Syn is known to be an important pharmaceutical target for Parkinson’s disease.
In 2013, scientists at the Michael J. Fox Foundation (MJFF) published a research report in the Journal of Parkinson’s Disease stating, “the ability to image alpha-synuclein deposition in the brain would be a game changing achievement for the Parkinson’s disease field”. ICBI has addressed this challenge.
News
ICBII Announces Approval of Its 7th Patent on Blood-Brain Barrier Permeable Technology, Moving Closer to Clinical Trials on its drugs for Alzheimer’s, Parkinson’s, and Other Neuro-Degenerative Diseases
NEWS PROVIDED BY Innovative California Biosciences International, Inc. Sep 22, 2021, 20:26 ET LA JOLLA, Calif., Sept. 22, 2021 /PRNewswire/ -- Innovative California Biosciences International, Inc., ("ICBII"), has announced the approval of…
Read More
How This Entrepreneur Is Working To Cure Neural Diseases
Joresa Blount Contributor Enterprise & Cloud Dr. Ram Bhatt, the Founder and Chief Scientist of ICB International, Inc. is one of the few scientists in the world who has developed…
Read More
2019 Market Report: Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030
ICBII Interview Transcript-Chapter 12.3.2 and Globe Newswire, March 29, 2019 https://www.globenewswire.com/news-release/2019/03/29/1788328/0/en/2019-Market-Report-Novel-Technologies-for-Delivery-of-Proteins-Antibodies-and-Nucleic-Acids-Forecast-to-2030.html Ram Bhatt CEO, Chairman and Founder ICB International Roots Analysis: Can you tell us about ICB International? ICB International,…
Read More